SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lyka Labs - Quaterly Results

23 May 2023 Evaluate
The sales slipped to Rs. 194.55 millions for the March 2023 quarter as against Rs. 276.83 millions during the year-ago period.The Net Loss for the quarter ended March 2023 is Rs. -30.03 millions as compared to Net Loss of Rs. -152.35 millions of corresponding quarter ended March 2022Operating profit for the quarter ended March 2023 decreased to 33.46 millions as compared to 122.22 millions of corresponding quarter ended March 2022.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202303 202203 % Var 202303 202203 % Var 202303 202203 % Var
Sales 194.55 276.83 -29.72 805.93 1643.49 -50.96 805.93 1643.49 -50.96
Other Income 6.15 6.60 -6.82 34.52 27.20 26.91 34.52 27.20 26.91
PBIDT 33.46 122.22 -72.62 190.52 1002.19 -80.99 190.52 1002.19 -80.99
Interest 28.13 29.10 -3.33 115.70 199.21 -41.92 115.70 199.21 -41.92
PBDT 3.94 65.09 -93.95 3.08 756.30 -99.59 3.08 756.30 -99.59
Depreciation 33.22 91.31 -63.62 135.16 153.89 -12.17 135.16 153.89 -12.17
PBT -29.28 -26.22 11.67 -132.08 602.41 -121.93 -132.08 602.41 -121.93
TAX 0.75 126.13 -99.41 0.78 203.38 -99.62 0.78 203.38 -99.62
Deferred Tax 4.23 126.13 -96.65 -1.29 203.38 -100.63 -1.29 203.38 -100.63
PAT -30.03 -152.35 -80.29 -132.86 399.03 -133.30 -132.86 399.03 -133.30
Equity 306.90 286.90 6.97 306.90 286.90 6.97 306.90 286.90 6.97
PBIDTM(%) 17.20 44.15 -61.04 23.64 60.98 -61.23 23.64 60.98 -61.23

Lyka Labs Share Price

57.60 1.05 (1.86%)
16-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1693.15
Dr. Reddys Lab 1221.25
Cipla 1230.75
Zydus Lifesciences 939.20
Lupin 2326.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×